LAVA Therapeutics $100.5 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Gyroscope Therapeutics $148.0 million Series C equity financing
We advised Gyroscope Therapeutics on its private placement of preferred stock
Charles River Laboratories International $1 billion senior notes offering
We advised Charles River Laboratories on the high-yield debt offering
Solid Biosciences $143.75 million follow-on equity offering
We advised the joint book-running managers on the stock offering
Connect Biopharma $219.9 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Anthem $3.5 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
Illumina $1 billion notes offering
We advised the underwriters on the investment-grade debt offering
MediaAlpha $370.3 million secondary offering
We advised the underwriters on the SEC-registered stock offering
Oncopeptides SEK 1.1 billion private placing of new shares
We advised Oncopeptides on the private placement of shares
Oak Street Health $920 million convertible senior notes offering
We advised the initial purchasers on the Rule 144A offering